My Thoughts

Leveraging my experience as a co-founder of a biotechnology start-up, corporate development leader, and investor to discuss tactical and strategic considerations for building great biotech and pharma companies.

(Don’t Fear) The Partner: Why Signing An Early Strategic Biotech Partnership is Not the Beginning of the End

Here are three common fears regarding early-stage strategic partnerships, and ways a founder or investor can overcome them to be successful.

Drew Hertig, MBA, CLP

Jun 18, 20248 min read

58 views

0 comments

San Diego Life Science Funding Rebounds BIG in Q1 2024, But Will It Last?

Welcome back to biotech beach! Capital raised in Q1 2024 for San Diego-based life science companies jumped 324% from same period last...

Drew Hertig, MBA, CLP

Apr 10, 20243 min read

47 views

0 comments

3 Ways Artificial Intelligence Will Unlock Substantial Value in Drug Development

Artificial Intelligence/Machine Learning (AI/ML) has the potential to significantly lower the costs of drug development and improve...

Drew Hertig, MBA, CLP

Feb 6, 20248 min read

108 views

0 comments

5 Reasons Biotech Valuations Go Down When Inflation Goes Up (and what you can do about it)

Unfortunately for biotechnology companies, their products have long development timelines and are perceived to be a high-risk investment....

Drew Hertig, MBA, CLP

Nov 26, 20238 min read

99 views

0 comments

Top Three Biotech Partnering Drivers for 2023

Biotech stocks have been beat up since February 2021, with the XBI index still down ~50% from record highs Headwinds in 2022 stemming...

Drew Hertig, MBA, CLP

Jan 11, 20234 min read

7 views

0 comments

Small Cap Biotech: When Will the 2021 Bear Market End?

Negative sentiment in the biotech industry has driven the SPDR S&P Biotech ETF (XBI) down more than 30% from February highs....

Drew Hertig, MBA, CLP

Dec 31, 20216 min read

38 views

0 comments